Schizophrenia: causes and treatments.

Curr Pharm Des

Lab. Neurobiología, CIMES, Facultad de Medicina, Universidad de Málaga, 29071-Málaga, Spain.

Published: June 2014

Schizophrenia is a major mental illness that is characterized by psychosis, apathy, social withdrawal and cognitive impairment. These abnormalities in patients results in impaired functioning in work, school, parenting, self-care, independent living, interpersonal relationships, and leisure. Although the search for the biological correlates of schizophrenia has met with limited success, new advances in genetics and pharmacology are promising. Here, we describe the symptoms, causes, diagnosis, strategies for treatment, and clinical impact of the currently available medications.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612811319360006DOI Listing

Publication Analysis

Top Keywords

schizophrenia treatments
4
treatments schizophrenia
4
schizophrenia major
4
major mental
4
mental illness
4
illness characterized
4
characterized psychosis
4
psychosis apathy
4
apathy social
4
social withdrawal
4

Similar Publications

The Relationships Between Multidimensional Schizotypy and Metacognitive Beliefs.

Psychol Rep

January 2025

School of Psychology, Faculty of Society and Design, Bond University, Gold Coast, QLD, Australia.

There has been a recent surge in schizotypy and metacognition research. Metacognition is an umbrella term for higher-order thought processes. Here, we focussed on maladaptive metacognitive beliefs, which are beliefs related to one's thought processes and often play an important role in the preponderance of psychological disorders.

View Article and Find Full Text PDF

Background: Psychoeducation programs can reduce the risk of recurrence and readmission in patients with schizophrenia. However, almost all previous studies of program efficacy have included only patients completing the program, which may not be possible in all cases. The objective of this pilot cohort study was to compare the prognoses of inpatients with schizophrenia who did or did not complete a well-established institutional psychoeducation program.

View Article and Find Full Text PDF

Schizophrenia is a chronic and severe mental disorder. It is currently treated with antipsychotic drugs (APD). However, APD's work only in a limited number of patients and may have cognition impairing side effects.

View Article and Find Full Text PDF

Background: Relapse following a first episode of schizophrenia (FES) is common and often results in serious adverse psychosocial consequences. Treatment non-adherence is a key risk factor for relapse, but why relapse occurs despite antipsychotic treatment adherence remains unclear. This study examined the differences in FES psychopathology trajectories over 24-months with assured long-acting injectable antipsychotic (LAIA) treatment, to control for treatment adherence between those who relapsed and those who did not and what moderates these group differences.

View Article and Find Full Text PDF

Importance: Delivery of mental health care through telehealth (telemental health care) increased after the onset of the COVID-19 pandemic. Little is known about the speed of adoption (diffusion) of telemental health in the care in the care of individuals with schizophrenia.

Objectives: To characterize telemental health care diffusion in mental health agencies serving Medicaid beneficiaries with schizophrenia and the beneficiary-level association of telemental health care use with race and ethnicity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!